The primary cause of cancer death is metastatic disease. Metastasis management is performed with highly toxic and non-specific therapies (e.g. chemotherapies) that are only partially efficacious and seriously affect the quality of life of patients. Aptadel Therapeutics is developing a compound that targets cancer cells and reduces its metastatic potential, while leaving healthy cells unharmed. The core of the technology is based on RNA aptamers (“chemical antibodies”) that bind with high affinity and specificity to the EphA2 receptor, overexpressed in a wide range of tumors. The technology has been validated in multiple cell lines derived from different cancer types (inhibition of cell migration, invasion and colony formation) and in vivo in a limited number of cancer mouse models (reduction of metastasis formation). Here we seek to thoroughly validate these RNA aptamers as a pan-cancer anti-metastatic agent in CDX/PDX mouse models of the most aggressive and deadliest cancer types.